3 Reasons to Buy Luckin Coffee Stock in 2026

Luckin Coffee reported strong momentum with third-quarter net revenue up 50.2% year‑over‑year to $2.14 billion, driven by 3,008 new store openings and same‑store sales growth of 14.4%, outpacing peers like Starbucks. After recovering from a 2019–2020 accounting scandal and a $180 million SEC penalty, new management is pursuing aggressive international expansion — including five NYC locations and potential acquisition targets such as Blue Bottle — while trading at a forward P/E of ~15 versus Starbucks at ~36; management plans a U.S. relisting, which could re-rate the stock. Investors should weigh robust top‑line growth and attractive valuation against residual legal/governance risks and the execution challenge of scaling in competitive international markets.

Analysis

Market structure: Luckin (OTC: LKNC.Y) is a direct winner — China-store adds (+3,008 YTD) and same-store sales +14.4% vs Starbucks (SBUX) +1% give Luckin a near-term share-gain vector in China and an opportunity to use promotional pricing to buy global footfall. Losers: incumbents in value/commuter segments (small independent chains, low-end mall cafés) face margin pressure as Luckin levers scale; coffee-bean premium roasters could see pricing pressure if Luckin pursues low-cost supply contracts. Cross-asset: aggressive expansion raises capex/debt needs (bond issuance risk) and increases FX exposure to RMB — a >5% RMB depreciation vs USD would cut USD-translated profits materially.

Risk assessment: Tail risks include (1) U.S. relisting denial or new U.S./China regulatory action (probability ~15–25% next 12 months), (2) recurrence of governance/legal issues (10–15%), and (3) margin collapse from sustained 30–50% promo strategy (could shave 400–800bp gross margin). Immediate (days-weeks) risk is liquidity-driven 20–50% volatility on OTC flows; medium (3–12 months) hinge on Blue Bottle M&A noise and relisting guidance; long (1–3 years) depends on international unit economics proving positive at scale. Hidden dependency: international loss-leading promos are only affordable if China EBITDA stays >10% and FCF funds expansion.

Trade implications: Direct play — size long LKNC.Y as a tactical growth/turnaround position (12–24 month horizon) and limit OTC exposure to <=5% NAV given liquidity/regulatory tail risk. Pair trade — long LKNC.Y / short SBUX (dollar-neutral, 2:1 long:short weight) to capture valuation gap (P/E 15 vs 36) while hedging U.S. consumer cyclicality. Options — where available, prefer asymmetric exposure: buy 9–12 month call spreads on LKNC.Y (25% OTM buy / 60% OTM sell) to cap premium; if no options, size equity smaller. Sector rotation — overweight China consumer discretionary and underweight U.S. premium coffee for next 6–18 months.

Contrarian angles: Consensus treats OTC stigma as permanent — that undervalues a business growing revenue +50% YoY; however, consensus may underprice operational execution risk: rapid global openings can dilute margins and brand (historical parallel: fast-replicating F&B concepts that collapsed after hyper-growth). The mispricing window is finite: a U.S. relisting or Blue Bottle acquisition would likely re-rate LKNC.Y >100% from current levels; conversely, a governance/regulatory shock could wipe out >50% in a week. Action should therefore be staged and trigger-driven, not binary conviction-based.

Key Decisions for Investors

• Establish an initial 2–3% long position in LKNC.Y (OTC) within 30 days with a 12–24 month horizon; scale to a 5% position only if (a) next two quarterly revenue growth remains >30% YoY or (b) management confirms U.S. relisting timeline within 6–12 months. Set a tactical stop-loss at 20% and reassess position if liquidity spreads widen >50% relative to last 30-day average.
• Put on a dollar-neutral pair: long LKNC.Y (size consistent with 3% portfolio weight) and short SBUX equal to half the dollar exposure (1.5%) to capture valuation gap (P/E 15 vs 36); unwind or rebalance if the pair moves ±30% or if LKNC.Y announces a U.S. relisting (close short within 5 trading days of announcement).
• Use options to gain asymmetric upside: if listed, buy 9–12 month call spreads on LKNC.Y sized to equal 1–2% delta exposure (buy ~25% OTM, sell ~60% OTM) to limit premium outlay. If options are unavailable, limit direct equity exposure and instead overweight China-consumer ETFs (e.g., KWEB) by +1–2% to capture correlation to Luckin's China performance.
• Cap aggregate OTC/illiquid single-name positions at 5% of portfolio NAV. Monitor three explicit triggers over next 90 days — (1) U.S. relisting date, (2) any new SEC/China regulatory notices, (3) confirmation of a Blue Bottle bid — and reduce exposure by 50% on any negative trigger or increase to target weights only on positive confirmation.